8-[(1S,3S,5R)-3-methyl-5-[3-(4-methylpiperazin-1-yl)-2-oxopropyl]cyclohexyl]quinoxaline-5-carbonitrile
C24H31N5O — CID 159636669
Data last refreshed: (MolForge compound catalog, from PubChem)
About 8-[(1S,3S,5R)-3-methyl-5-[3-(4-methylpiperazin-1-yl)-2-oxopropyl]cyclohexyl]quinoxaline-5-carbonitrile
8-[(1S,3S,5R)-3-methyl-5-[3-(4-methylpiperazin-1-yl)-2-oxopropyl]cyclohexyl]quinoxaline-5-carbonitrile (PubChem CID 159636669) has the molecular formula C24H31N5O and a molecular weight of 405.55 g/mol. Its IUPAC name is 8-[(1S,3S,5R)-3-methyl-5-[3-(4-methylpiperazin-1-yl)-2-oxopropyl]cyclohexyl]quinoxaline-5-carbonitrile.
Molecular Properties
| Compound Name | 8-[(1S,3S,5R)-3-methyl-5-[3-(4-methylpiperazin-1-yl)-2-oxopropyl]cyclohexyl]quinoxaline-5-carbonitrile |
|---|---|
| PubChem CID | 159636669 |
| Molecular Formula | C24H31N5O |
| Molecular Weight | 405.55 g/mol |
| Exact Mass | 405.25 |
| IUPAC Name | 8-[(1S,3S,5R)-3-methyl-5-[3-(4-methylpiperazin-1-yl)-2-oxopropyl]cyclohexyl]quinoxaline-5-carbonitrile |
| SMILES | C[C@H]1C[C@@H](CC(=O)CN2CCN(C)CC2)C[C@@H](c2ccc(C#N)c3nccnc23)C1 |
| InChI | InChI=1S/C24H31N5O/c1-17-11-18(14-21(30)16-29-9-7-28(2)8-10-29)13-20(12-17)22-4-3-19(15-25)23-24(22)27-6-5-26-23/h3-6,17-18,20H,7-14,16H2,1-2H3/t17-,18+,20-/m0/s1 |
| InChIKey | MPVIDMYVHQVHPW-NSHGMRRFSA-N |
| XLogP | 3.23 |
| TPSA | 73.12 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 405.55 |
| LogP ≤ 5 | 3.23 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 159636669 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.